4Evans TR, Pentheroudakis G, Paul J, et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma[J]. Ann Oncol, 2002 ,13(9):1469-1478.
5Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma[J]. Ann Oncol,2003,14(8):1258-1263.
6Miwa M, Ura M, Nishida M,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer, 1998,34(8):1274-1281.
7Liu G, Franssen E, Fitch M,et al. Patient preferences for oral versus intravenous palliative chemotherapy[J].J Clin Oncol,1997,15(1):110-115.
8Schüller J, Cassidy J, Dumont E,et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients[J].Cancer Chemother Pharmacol,2000,45(2):291-297.
